Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • State of the Art Mini Review
  • Published:

Acute Leukemia Forum 2000, Advances and Controversies in the Therapy of Acute Myelogenous Leukemia

MDR modulation in acute myelogenous leukemia: is it dead?

Leukemia volume 15, pages 666–667 (2001)Cite this article

The foundation for why drug resistance is seen so frequently may be related to the inherent heterogeneity within tumors. Drug resistance is clearly not a single entity, but a multiplicity of entities of which regulation at the cell surface is perhaps only one small part. The multidrug resistance gene complex (MDR) may be the first line of defense against cytotoxic agents, preventing them from remaining inside the cell long enough to inflict damage.

MDR proteins are active membrane transport pumps that efflux exogenous and endogenous substances from cells via calcium-mediated efflux pumps. Overexpression of MDR-associated transport proteins is associated with clinical drug resistance to natural products. Agents that have been demonstrated to interfere with drug efflux include the calcium channel blockers, such as verapamil, and other agents, such as cyclosporin A (CsA) and PSC-833.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. List AF, Kopeky KJ, Willman CL, Spier C, Dorr R, Flanerty L, Hynes H, Appelbaum F . Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high risk AML: a Southwest Oncology Group (SWOG) study Blood 1998 92: (Suppl. 1) 1281a (Abstr.)

    Google Scholar 

  2. Lee EJ, George SL, Caligiuri M et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420 J Clin Oncol 1999 17: 2831–2839

    Article  CAS  Google Scholar 

  3. Chauncey TR, Rankin C, Anderson JE et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group Study 9617 Leukemia Research 2000 24: 567–574

    Article  CAS  Google Scholar 

  4. Advani R, Visani G, Milligan D et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC) Adv Exp Med Biol 1999 457: 47–56

    Article  CAS  Google Scholar 

  5. Ross DD . Novel mechanisms of drug resistance in leukemia Leukemia 2000 14: 467–473

    Article  CAS  Google Scholar 

  6. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA . P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells Br J Haematol 2000 108: 48–54

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Maryland Greenbaum Cancer Center, 22 S Greene Street, Room S9D15, Baltimore, MD 21201, USA

    JE Karp

Authors
  1. JE Karp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karp, J. MDR modulation in acute myelogenous leukemia: is it dead?. Leukemia 15, 666–667 (2001). https://doi.org/10.1038/sj.leu.2402055

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402055

This article is cited by

Search

Advanced search

Quick links